Literature DB >> 23296451

Small targeted cytotoxics: current state and promises from DNA-encoded chemical libraries.

Nikolaus Krall1, Jörg Scheuermann, Dario Neri.   

Abstract

The targeted delivery of potent cytotoxic agents has emerged as a promising strategy for the treatment of cancer and other serious conditions. Traditionally, antibodies against markers of disease have been used as drug-delivery vehicles. More recently, lower molecular weight ligands have been proposed for the generation of a novel class of targeted cytotoxics with improved properties. Advances in this field crucially rely on efficient methods for the identification and optimization of organic molecules capable of high-affinity binding and selective recognition of target proteins. The advent of DNA-encoded chemical libraries allows the construction and screening of compound collections of unprecedented size. In this Review, we survey developments in the field of small ligand-based targeted cytotoxics and show how innovative library technologies will help develop the drugs of the future.
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23296451     DOI: 10.1002/anie.201204631

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  39 in total

1.  Novel Small Molecule Probes for Metastatic Melanoma.

Authors:  Anyanee Kamkaew; Nanyan Fu; Weibo Cai; Kevin Burgess
Journal:  ACS Med Chem Lett       Date:  2016-12-09       Impact factor: 4.345

2.  Bispecific small molecule-antibody conjugate targeting prostate cancer.

Authors:  Chan Hyuk Kim; Jun Y Axup; Brian R Lawson; Hwayoung Yun; Virginie Tardif; Sei Hyun Choi; Quan Zhou; Anna Dubrovska; Sandra L Biroc; Robin Marsden; Jason Pinstaff; Vaughn V Smider; Peter G Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-14       Impact factor: 11.205

3.  Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation.

Authors:  Moreno Wichert; Nikolaus Krall; Willy Decurtins; Raphael M Franzini; Francesca Pretto; Petra Schneider; Dario Neri; Jörg Scheuermann
Journal:  Nat Chem       Date:  2015-01-26       Impact factor: 24.427

4.  A human monoclonal antibody specific to placental alkaline phosphatase, a marker of ovarian cancer.

Authors:  Niccolò Ravenni; Marcel Weber; Dario Neri
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

Review 5.  Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site.

Authors:  Jonathan D Kiefer; Dario Neri
Journal:  Immunol Rev       Date:  2016-03       Impact factor: 12.988

6.  Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis.

Authors:  Samuele Cazzamalli; Alberto Dal Corso; Fontaine Widmayer; Dario Neri
Journal:  J Am Chem Soc       Date:  2018-01-27       Impact factor: 15.419

7.  Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2.

Authors:  Samuele Cazzamalli; Barbara Ziffels; Fontaine Widmayer; Patrizia Murer; Giovanni Pellegrini; Francesca Pretto; Sarah Wulhfard; Dario Neri
Journal:  Clin Cancer Res       Date:  2018-04-24       Impact factor: 12.531

8.  Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix.

Authors:  Rémy Gébleux; Marco Stringhini; Ruben Casanova; Alex Soltermann; Dario Neri
Journal:  Int J Cancer       Date:  2016-12-30       Impact factor: 7.396

9.  Targeted Delivery of Cytotoxic Drugs: Challenges, Opportunities and New Developments.

Authors:  Samuele Cazzamalli; Alberto Dal Corso; Dario Neri
Journal:  Chimia (Aarau)       Date:  2017-10-25       Impact factor: 1.509

10.  Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates.

Authors:  Rémy Gébleux; Sarah Wulhfard; Giulio Casi; Dario Neri
Journal:  Mol Cancer Ther       Date:  2015-08-20       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.